Viewing Study NCT06646770



Ignite Creation Date: 2024-10-25 @ 7:50 PM
Last Modification Date: 2024-10-26 @ 3:43 PM
Study NCT ID: NCT06646770
Status: NOT_YET_RECRUITING
Last Update Posted: None
First Post: 2024-10-16

Brief Title: SEgmentectomy Versus Lobectomy in T1C Non-Small Cell Lung Cancer SELTIC
Sponsor: None
Organization: None

Study Overview

Official Title: Segmentectomy Versus Lobectomy in Clinical T1c Non-Small Cell Lung Cancer A Non-Inferiority Trial
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: SELTIC
Brief Summary: The goal of this clinical trial is to investigate the role of segmentectomy in clinical T1c 2-3 cm non-small cell lung cancer NSCLC The main questions we aim to answer are

1 Is segmentectomy non-inferior to lobectomy in cT1c NSCLC in terms of overall and recurrence free survival
2 What are the mortality and morbidity rates of segmentectomy compared to lobectomy

Researchers will compare segmentectomy and lobectomy in terms of overall and recurrence free survival

Participants will

Undergo either pulmonary lobectomy or segmentectomy with mediastinal nodal dissection
Be followed up with a chest CT in every 3 months in first year every 6 months in second year and every year for following 3 years
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None